Technology Transfer

Case Western Reserve University's Technology Transfer Office (TTO) serves our innovators with full-spectrum intellectual property services. For both faculty and students, we provide support for intellectual property and commercialization that spans the research & development continuum. We serve our researchers by assessing and building upon the commercial potential of new ideas and inventions.

Through interaction with our inventors, regional and national networks, including our affiliate healthcare systems, and potential commercial partners, we endeavor to determine the best path of translation and ultimate commercialization for University intellectual assets.

Consistent with the University's mission, the Technology Transfer Office is working towards enhancing its role in the promotion of an inclusive culture of global citizenship by exploring issues of access to essential medicines by resource-limited countries. This work includes moving towards the Universities Allied for Essential Medicine's Global Access Licensing Framework.

Recent News

Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University
--AccessWire, May 12, 2022

Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
--PAVmed, May 9, 2022

Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
--PAVmed, April 4, 2022

NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
--NervGen, March 31, 2022

Please visit our TTO News webpage for more articles and press releases about TTO success stories.

For Questions About...

  • Your Invention Disclosure Form (IDF), please contact Joy Chen at 216.368.0362.
  • A Material Transfer Agreement (MTA) please contact Walid Jalabi at 216.368.2151.
  • A Data Use Agreement (DUA), please contact
  • Anything else, please contact Daniel Pendergast at 216.368.0184.